{"publication_identifier":{"issn":["0889-1591"]},"author":[{"last_name":"Proschinger","first_name":"Sebastian","full_name":"Proschinger, Sebastian"},{"first_name":"Sergen","last_name":"Belen","full_name":"Belen, Sergen"},{"first_name":"Frederike","last_name":"Adammek","full_name":"Adammek, Frederike"},{"id":"117661","first_name":"Marit Lea","last_name":"Schlagheck","orcid":"0000-0002-8913-6080 ","full_name":"Schlagheck, Marit Lea"},{"first_name":"Annette","last_name":"Rademacher","full_name":"Rademacher, Annette"},{"full_name":"Schenk, Alexander","first_name":"Alexander","last_name":"Schenk"},{"last_name":"Warnke","first_name":"Clemens","full_name":"Warnke, Clemens"},{"full_name":"Bloch, Wilhelm","first_name":"Wilhelm","last_name":"Bloch"},{"last_name":"Zimmer","first_name":"Philipp","full_name":"Zimmer, Philipp"}],"status":"public","year":"2024","title":"Sportizumab – Multimodal progressive exercise over 10 weeks decreases Th17 frequency and CD49d expression on CD8+ T cells in relapsing-remitting multiple sclerosis: A randomized controlled trial","intvolume":"       124","date_updated":"2025-06-02T09:53:19Z","publication_status":"published","_id":"60093","publisher":"Elsevier BV","language":[{"iso":"eng"}],"page":"397-408","volume":124,"doi":"10.1016/j.bbi.2024.12.017","user_id":"117661","citation":{"ieee":"S. Proschinger <i>et al.</i>, “Sportizumab – Multimodal progressive exercise over 10 weeks decreases Th17 frequency and CD49d expression on CD8+ T cells in relapsing-remitting multiple sclerosis: A randomized controlled trial,” <i>Brain, Behavior, and Immunity</i>, vol. 124, pp. 397–408, 2024, doi: <a href=\"https://doi.org/10.1016/j.bbi.2024.12.017\">10.1016/j.bbi.2024.12.017</a>.","apa":"Proschinger, S., Belen, S., Adammek, F., Schlagheck, M. L., Rademacher, A., Schenk, A., Warnke, C., Bloch, W., &#38; Zimmer, P. (2024). Sportizumab – Multimodal progressive exercise over 10 weeks decreases Th17 frequency and CD49d expression on CD8+ T cells in relapsing-remitting multiple sclerosis: A randomized controlled trial. <i>Brain, Behavior, and Immunity</i>, <i>124</i>, 397–408. <a href=\"https://doi.org/10.1016/j.bbi.2024.12.017\">https://doi.org/10.1016/j.bbi.2024.12.017</a>","chicago":"Proschinger, Sebastian, Sergen Belen, Frederike Adammek, Marit Lea Schlagheck, Annette Rademacher, Alexander Schenk, Clemens Warnke, Wilhelm Bloch, and Philipp Zimmer. “Sportizumab – Multimodal Progressive Exercise over 10 Weeks Decreases Th17 Frequency and CD49d Expression on CD8+ T Cells in Relapsing-Remitting Multiple Sclerosis: A Randomized Controlled Trial.” <i>Brain, Behavior, and Immunity</i> 124 (2024): 397–408. <a href=\"https://doi.org/10.1016/j.bbi.2024.12.017\">https://doi.org/10.1016/j.bbi.2024.12.017</a>.","short":"S. Proschinger, S. Belen, F. Adammek, M.L. Schlagheck, A. Rademacher, A. Schenk, C. Warnke, W. Bloch, P. Zimmer, Brain, Behavior, and Immunity 124 (2024) 397–408.","mla":"Proschinger, Sebastian, et al. “Sportizumab – Multimodal Progressive Exercise over 10 Weeks Decreases Th17 Frequency and CD49d Expression on CD8+ T Cells in Relapsing-Remitting Multiple Sclerosis: A Randomized Controlled Trial.” <i>Brain, Behavior, and Immunity</i>, vol. 124, Elsevier BV, 2024, pp. 397–408, doi:<a href=\"https://doi.org/10.1016/j.bbi.2024.12.017\">10.1016/j.bbi.2024.12.017</a>.","bibtex":"@article{Proschinger_Belen_Adammek_Schlagheck_Rademacher_Schenk_Warnke_Bloch_Zimmer_2024, title={Sportizumab – Multimodal progressive exercise over 10 weeks decreases Th17 frequency and CD49d expression on CD8+ T cells in relapsing-remitting multiple sclerosis: A randomized controlled trial}, volume={124}, DOI={<a href=\"https://doi.org/10.1016/j.bbi.2024.12.017\">10.1016/j.bbi.2024.12.017</a>}, journal={Brain, Behavior, and Immunity}, publisher={Elsevier BV}, author={Proschinger, Sebastian and Belen, Sergen and Adammek, Frederike and Schlagheck, Marit Lea and Rademacher, Annette and Schenk, Alexander and Warnke, Clemens and Bloch, Wilhelm and Zimmer, Philipp}, year={2024}, pages={397–408} }","ama":"Proschinger S, Belen S, Adammek F, et al. Sportizumab – Multimodal progressive exercise over 10 weeks decreases Th17 frequency and CD49d expression on CD8+ T cells in relapsing-remitting multiple sclerosis: A randomized controlled trial. <i>Brain, Behavior, and Immunity</i>. 2024;124:397-408. doi:<a href=\"https://doi.org/10.1016/j.bbi.2024.12.017\">10.1016/j.bbi.2024.12.017</a>"},"publication":"Brain, Behavior, and Immunity","extern":"1","date_created":"2025-06-02T09:48:43Z","type":"journal_article"}